Search

Displaying results 6941 - 6950 of 7041 in total
  1. Drug

    Resminostat

    go.drugbank.com/drugs/DB12392
    Investigational

    Resminostat has been used in trials studying the treatment of Sezary Syndrome, Mycosis fungoides, Hodgkin's Lymphoma, Hepatocellular Carcinoma, and Lymphoma, T-Cell, Cutaneous, among others.

  2. Drug

    Amediplase

    go.drugbank.com/drugs/DB06679
    Experimental

    Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase.

  3. Drug

    Biomodulin T

    go.drugbank.com/drugs/DB16529
    Experimental

    Biomodulin T is a polypeptide fraction from bovine thymus with immunomodulatory effects.

    Synonyms: Biomodulina T
  4. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]

  5. Drug

    AMG-553

    go.drugbank.com/drugs/DB18346
    Investigational

    AMG-553 is an adoptive, anti-FLT3 chimeric antigen receptor T-cell therapy generated through transduction of autologous T-cells with a self-inactivating human immunodeficiency virus-1 based lentiviral

  6. Drug

    TCB-008

    go.drugbank.com/drugs/DB18352
    Investigational

    TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.

  7. Drug

    Col-Treg

    go.drugbank.com/drugs/DB18451
    Experimental

    Col-Treg is an autologous T-cell therapy comprising type I regulatory T-cells specific for human type II collagen.[A261635]

    Synonyms: Purified autologous type 1 regulatory T lymphocytes specific for human type II collagen
  8. Drug

    MDR-101

    go.drugbank.com/drugs/DB18513
    Investigational

    MDR-101 is a CD34+ hematopoietic stem and progenitor cells with CD3+ T-cells

  9. Drug

    FCR001

    go.drugbank.com/drugs/DB18595
    Investigational

    FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.

  10. Drug

    WU-CART-007

    go.drugbank.com/drugs/DB18617
    Investigational

    WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.

    Synonyms: an allogeneic, fratricide-resistant genetically modified T cell transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7